Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

by Jesús Zurdo, Andreas Arnell, Olga Obrezanova, Noel Smith, Ramón Gómez de la Cuesta, Thomas R. A. Gallagher, Rebecca Michael, Yvette Stallwood, Caroline Ekblad, Lars Abrahmsén, Ingmarie Höidén-Guthenberg
Published 2015-01-01

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

by Sophia Ceder, Sofi E. Eriksson, Ying Yu Liang, Emarndeena H. Cheteh, Si Min Zhang, Kenji M. Fujihara, Julie Bianchi, Vladimir J. N. Bykov, Lars Abrahmsen, Nicholas J. Clemons, Pär Nordlund, Sean G. Rudd, Klas G. Wiman
Published 2021-07-01

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death

by Sophia Ceder, Sofi E Eriksson, Emarndeena H Cheteh, Swati Dawar, Mariana Corrales Benitez, Vladimir J N Bykov, Kenji M Fujihara, Mélodie Grandin, Xiaodun Li, Susanne Ramm, Corina Behrenbruch, Kaylene J Simpson, Frédéric Hollande, Lars Abrahmsen, Nicholas J Clemons, Klas G Wiman
Published 2021-02-01

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

by David S. Liu, Cuong P. Duong, Sue Haupt, Karen G. Montgomery, Colin M. House, Walid J. Azar, Helen B. Pearson, Oliver M. Fisher, Matthew Read, Glen R. Guerra, Ygal Haupt, Carleen Cullinane, Klas G. Wiman, Lars Abrahmsen, Wayne A. Phillips, Nicholas J. Clemons
Published 2017-03-01